TAP taps McKenzie
This article was originally published in The Tan Sheet
Executive SummaryAlan MacKenzie serves as president of Takeda/Abbott Labs joint venture TAP Pharmaceutical Products, effective Sept. 1. Most recently, MacKenzie headed Takeda Pharmaceuticals North America after holding other senior positions, such as president of sales and director of marketing. The exec succeeds Thomas Watkins upon the expiration of his six-year term. After assisting in the transition, Watkins will return to senior management at Abbott, where he previously served as VP-Abbott Health Systems...
You may also be interested in...
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.